Home to the Schaeffer Center for Health Policy & Economics and the Schaeffer Fellows in Government Service. Transforming policy through rigorous, independent research and close engagement with public and private sector leaders.
USC Schaeffer
Loading...
Cell and gene therapies are transforming medicine, but significant questions remain about cost, reimbursement & access. Hear USC Schaeffer's Darius Lakdawalla break down these issues in tomorrow's webinar from @mhexecutive.bsky.social.
✒️Registration: globalmeet.webcasts.com/starthere.js...
USC Schaeffer's Erin Duffy shares why reviewing medical bills closely can make a real difference for patients facing unexpected charges.
"The United States has already invested in developing curative therapies. Without a financing model that matches their value, those cures will remain out of reach for many patients," writes USC Schaeffer's William Padula in @statnews.com.
GLP-1s may deliver the greatest health and economic benefits to disadvantaged populations, who historically have faced greater barriers to sustained weight loss through behavioral interventions.
New NBER working paper from USC Schaeffer scholars ⬇️
A proposed California ballot measure to cap medical executives' pay is unlikely to reduce patient costs, USC Schaeffer's Glenn Melnick tells @kffhealthnews.org.
Medicare could unlock a trove of valuable clinical trial data through relatively modest changes to reporting requirements, USC Schaeffer Scholars Sidra Haye and Mireille Jacobson write in @jamahealthforum.com.
Medicare’s cap on monthly #insulin costs reduced beneficiaries’ spending on the drug by 21% and increased use among those who previously had especially high costs, finds new USC Schaeffer research in JAMA.
Today’s near-retirees are healthier and more capable than ever. For those who are able to, choosing to work just one more year can improve their well-being & America's fiscal outlook.
New @thehill.com op-ed from USC Schaeffer Founding Director Dana Goldman & CMS Chief Economist Anup Malani.⬇️
At yesterday's FDA listening session on the commissioner's voucher program, USC Schaeffer's Lowell Schiller said issuing formal rules or guidance would strengthen program integrity and provide greater certainty for product sponsors.
A Medicare policy providing coverage for promising treatments while more evidence is gathered has effectively created a two-tiered system for access to innovative medical technologies, new USC Schaeffer research shows.
Health care costs are especially worrisome for people 65 and older. Here's how to lower your health care costs during challenging times.
GLP-1s may deliver the greatest health and economic benefits to disadvantaged populations, who historically have faced greater challenges losing weight through behavioral interventions. - June 8, 2026
One of California’s largest healthcare unions is sponsoring two initiatives that would regulate community clinics and cap executive and managerial pay at hospitals and physician groups. In the most re...
More accurate reporting of trial-related care could generate valuable evidence about new treatments, promote representative trial enrollment and improve coverage decisions. - June 12, 2026
The monthly spending limit improved adherence among insulin users who previously had especially high costs, Schaeffer researchers found. - June 8, 2026
FDA should establish clear rules or guidance outlining how products are selected and evaluated for the program, along with appropriate guardrails. - June 4, 2026
A comparison of hospitals that do and do not participate in Coverage with Evidence Development (CED) finds that rural and low-income Medicare beneficiaries face reduced access to emerging technologies...
